Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.0010626992561105 -0.0114240170031881 0.00584484590860783
Stock impact report

Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan

IMMUNOMEDICS (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
Company Research Source: GlobeNewswire
Updated Phase 2 Results in Metastatic Triple-Negative Breast Cancer to be Presented at The 2018 San Antonio Breast Cancer Symposium (SABCS) Continue to Show Meaningful Clinical Benefit Consistent with Prior Results Pivotal Randomized Study in Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Metastatic Breast Cancer (mBC) MORRIS PLAINS, N.J., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presents updated Phase 2 results at the 2018 SABCS, confirming that monotherapy with sacituzumab govitecan achieved an objective response rate (ORR) of over 30 percent among heavily pre-treated patients with metastatic triple-negative breast cancer (mTNBC), with a manageable safety profile. “Response rates to chemotherapy are low in patients with pre-treated mTNBC, and clinically there is a high unmet need for mT Show less Read more
Impact Snapshot
Event Time:
IMMU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IMMU alerts
Opt-in for
IMMU alerts

from News Quantified
Opt-in for
IMMU alerts

from News Quantified